Public Expose 2022 : Phapros to Focus on Development on Innovations and Digitalization Strategies in 2022

JAKARTA, 25 Mei 2022 – The National Pharmaceutical BUMN Subsidiary, PT Phapros (PEHA), held the Annual General Meeting of Shareholders for the 2021 Fiscal Year which was followed by a public expose of the Company by inviting shareholders, potential investors, and the media to inform the company's achievements during 2021 and the first quarter of 2022. The annual event also contains explanations from the Board of Directors regarding the company's future strategies by responding to national and global macroeconomic conditions that have a direct or indirect impact on corporate performance.

According to the President Director of PT Phapros Tbk, Hadi Kardoko, during the past 202i, the company managed to record a fairly good financial and non-financial performance. The company successfully increased its net sales by 7.23% in 2021 compared to 2020.

"Although the company's assets have decreased by 4% compared to 2020, the company has also succeeded in increasing the cash ratio in 2021 by 122% compared to the previous year. This indicates that the company is growing in a healthy manner and has a relatively good ability to fulfill its financial obligations," Hadi said in Jakarta, Wednesday (25/5).

Achieving 9 awards, 6 certifications, and an increase of CSR activities by 40% compared to 2020, he further added that PEHA’s non-financial accomplishment is fervently recognized by stakeholders as a form of hard work by all dedicated employees in the company.

“We launched more than 10 new products last year in the therapeutic class (TC) for cardiovascular, orthopedic, health supplements, gastrointestinal, neurotropic, and oral corticosteroids. With the increasing need for public and medical personnel for high quality medicinal products, Phapros also contributes by releasing the latest research-based products."

According to Hadi, this year Indonesia's macroeconomic conditions, as well as the pharmaceutical sector, are getting better than the previous year when the pandemic still affecting most sectors. The growth of the pharmaceutical market in 2022 is predicted to reach 10.2 percent, higher than in 2021, which was only 9.4 percent at that time. And in 2023, it is estimated that this sector will grow by 11.2 percent.

"This year, the company will focus on growth and innovation strategies, particularly on organizing the company's portfolio, optimizing subsidiaries and re-structuring marketing operations. In addition, we will also carry out production efficiency, research arrangement and product development, business development, and company’s financial reinforcement," the Director added.

Digital transformation is also part of the company's grand strategies in 2022, including operational transformations by digitizing supply chains and production processes, as well as optimizing sales through e-commerce.

The Company also made changes in the Top Management Structure. Based on the results of today's GMS, it has been decided that there will be a replacement in the position of the Independent Commissioner, so that the structure of the Company's Board of Commissioners has changed into:

President Commissioner:  Maxi Rein Rondonuwu

Commissioner: Masrizal Achmad Syarief

Independent Commissioner: Chrisma Aryani Albandjar

Independent Commissioner: Bimo Wijayanto

As for the composition of the Board of Directors, there was a change in the positions of the Marketing Director and the Production Director of the Company, so that the Company's Board of Directors will be set as follows :

President Director: Hadi Kardoko

Director of Finance, Risk Management, and Human Capital: David Sidjabat

Marketing Director: Imelda Alini Pohan

Production Director: Ida Rahmi Kurniasih